MiMedx Group
Update in progressMDXG (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MiMedx Group, Inc. develops and distributes placental tissue allografts for wound care, surgical, and regenerative uses. It processes placental tissue, umbilical cord, and placental disc with its PURION method, delivering aseptically processed, terminally sterilized allografts that preserve growth factors and regulatory proteins. Products include EPIFIX, AMNIOFIX, AXIOFILL, and AMNIOEFFECT for wounds and surgeries. Sells through direct reps, distributors, and Vaporox alliance. Founded 2006, based in Marietta, Georgia.
Company score
- Sentiment
- -0.54
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.58
- Governance
- -0.78
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.34
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.44
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!